The complexity of cancer makes personalization vital to successful cancer treatment. We offer personalized care solutions to improve your outcomes.
Circulating Tumor Cells (CTCs)
Circulating tumor cells are cancer cells which have broken away from the primary tumor and entered the blood stream where they circulate and have the potential to generate metastatic disease. These cells can be isolated and identified and there is growing interest in their detection for the following purposes:
- detect early signs of a developing cancer,
- help to monitor existing cancers,
- produce an individual profile of which cancer drugs and which natural substances can be used to achieve the best treatment outcomes.
Cancer Stem Cells (CSCs)
Cancer stem cells are cancer cells found within tumors or hematological cancers that possess characteristics associated with normal stem cells.
RGCC
Research Genetics Cancer Center (RGCC) Group was established in 2004 by Dr. Ioannis Papasotiriou. The company is a pioneering, innovative organization working in the fields of medical genetics and, in particular, cancer genetics, chemosensitivity and chemo-resistance testing and in Research and Development within the pharmaceutical industry via RGCC Pharma Ltd. The company headquarters are in Switzerland, and the brand new, state-of-the art laboratories in Northern Greece are equipped with the most up-to-date technological, advanced and innovative equipment. RGCC has performed over 1800 tests since 2004.
RGCC Group offers general laboratory analysis for CTCs and for specific cancers including breast, colorectal, prostate, lung, melanoma and sarcomas. The test is performed from a simple blood sample and results are completed in 3-4 weeks.
RGCC Testing and Treatment
Melody, our FNP, has been certified and trained in using the RGCC testing.
Detailed treatment plans are provided for our patients.
Cancers Tested by RGCC:
1 Adrenocortical
2 Appendicial
3 Basal
4 Bladder
5 Brain (biopsy only)
6 Breast
7 Cervical
8 Cholangiosarcoma
9 Colorectal (also anal)
10 Endometrial
11 Esophagus (including Barret’s)
12 Gastric
13 Kidney
14 Leukemias (AML, CLL, ALL, CML)
15 Liver & Gallbladder
16 Lung (carcinoma, NSCLC, SCLC)
17 Lymphomas
18 Melanoma
19 Multiple Myeloma
20 Nasopharyngeal, head & neck
21 Ovary
22 Pancreas
23 Parotid
24 Peritoneal
25 Prostate
26 Renal
27 Sarcoma (Chondrosarcoma, Ewing’s sarcoma, Fibrosarcoma, Gastrointestinal stromal tumor,
Liposarcoma, Leiomyosarcoma, Osteosarcoma, Rhabdomyosarcoma, Synovial sarcoma)
28 Salivary
29 Screenings
30 Sinus
31 Squamous
32 Stomach
33 Testicular
34 Thymic
35 Tongue
36 Tonsillar
37 Thyroid
38 Unknown (CUP)
39 Uterus
40 Vocal cord
41 Vulva
Advanced Treatments from RGCC
These therapies are very specific and made personally for each patient. This is truly personalized care at its finest, scientifically based and requires many steps to get the product made correctly, then back to your health care provider as quickly as possible.
Supportive Oligonucleotide Technique (SOT) has been shown to be a very supportive treatment for cancer. SOT has the ability to induce apoptosis (cell death) in CTCs, CSCs and primary tumor cells. From a blood sample the CTCs are identified then a small molecule call microRNA is developed to match exactly into the key portion of the cancer cell that controls cell death. The SOT is injected intravenously, spreads throughout the body including past the blood-brain barrier, embeds into the cancer and will disrupt the ability of the cancer to replicate. SOT has a stealth like ability to avoid destruction and will work 24/7 to fight cancer for as long as 6 months. Repeat blood samples are used to create new SOT molecules that account for cancer cell mutations.
